JP2023546504A - ヒト対象におけるタウを減少させる方法 - Google Patents

ヒト対象におけるタウを減少させる方法 Download PDF

Info

Publication number
JP2023546504A
JP2023546504A JP2023525044A JP2023525044A JP2023546504A JP 2023546504 A JP2023546504 A JP 2023546504A JP 2023525044 A JP2023525044 A JP 2023525044A JP 2023525044 A JP2023525044 A JP 2023525044A JP 2023546504 A JP2023546504 A JP 2023546504A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tau
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525044A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022090158A5 (https=
JP2023546504A5 (https=
Inventor
アール． ガルペルン，ウェンディー
ティマース，マールテン
リーヴェン ケイ． ジェイコブス，トム
ナンディ，パルサ
リ，リンジュエ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2023546504A publication Critical patent/JP2023546504A/ja
Publication of JPWO2022090158A5 publication Critical patent/JPWO2022090158A5/ja
Publication of JP2023546504A5 publication Critical patent/JP2023546504A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023525044A 2020-10-26 2021-10-25 ヒト対象におけるタウを減少させる方法 Pending JP2023546504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105804P 2020-10-26 2020-10-26
US63/105,804 2020-10-26
PCT/EP2021/079543 WO2022090158A1 (en) 2020-10-26 2021-10-25 Methods of reducing tau in human subjects

Publications (3)

Publication Number Publication Date
JP2023546504A true JP2023546504A (ja) 2023-11-02
JPWO2022090158A5 JPWO2022090158A5 (https=) 2024-09-17
JP2023546504A5 JP2023546504A5 (https=) 2024-09-17

Family

ID=78402146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525044A Pending JP2023546504A (ja) 2020-10-26 2021-10-25 ヒト対象におけるタウを減少させる方法

Country Status (11)

Country Link
US (1) US20220127345A1 (https=)
EP (1) EP4232155A1 (https=)
JP (1) JP2023546504A (https=)
KR (1) KR20230093499A (https=)
CN (1) CN116916955A (https=)
AU (1) AU2021367878A1 (https=)
CA (1) CA3199806A1 (https=)
IL (1) IL302386A (https=)
MX (1) MX2023004831A (https=)
TW (1) TW202233666A (https=)
WO (1) WO2022090158A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021111A (ko) 2022-08-09 2024-02-16 레르 리키드 쏘시에떼 아노님 뿌르 레뜌드 에렉스뿔라따시옹 데 프로세데 조르즈 클로드 공기 분리 장치 및 공기 분리 방법

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170351A1 (en) * 2017-03-16 2018-09-20 Janssen Biotech, Inc. Anti-phf-tau antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP6214161B2 (ja) * 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN117820467A (zh) * 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
WO2020223279A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
EP4232472A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Method of safe administration of anti-tau antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170351A1 (en) * 2017-03-16 2018-09-20 Janssen Biotech, Inc. Anti-phf-tau antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WENDY R. GALPERN; ET AL: "P1-052 A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY PHARMACOKINETICS, AND PHAR", ALZHEIMER'S & DEMENTIA, vol. VOL.15, NR.7, JPN5024004790, July 2019 (2019-07-01), US, pages 252 - 253, ISSN: 0005828767 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021111A (ko) 2022-08-09 2024-02-16 레르 리키드 쏘시에떼 아노님 뿌르 레뜌드 에렉스뿔라따시옹 데 프로세데 조르즈 클로드 공기 분리 장치 및 공기 분리 방법

Also Published As

Publication number Publication date
MX2023004831A (es) 2023-07-12
TW202233666A (zh) 2022-09-01
US20220127345A1 (en) 2022-04-28
KR20230093499A (ko) 2023-06-27
IL302386A (en) 2023-06-01
CA3199806A1 (en) 2022-05-05
AU2021367878A1 (en) 2023-06-22
EP4232155A1 (en) 2023-08-30
WO2022090158A1 (en) 2022-05-05
CN116916955A (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
RU2518351C2 (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
US11312763B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
JP2022058369A (ja) アルツハイマー病治療方法
TW201900682A (zh) 抗ｐｈｆ－ｔａｕ抗體及其用途
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
JP2023546504A (ja) ヒト対象におけるタウを減少させる方法
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
HK40100364A (zh) 减少人类受试者中的tau的方法
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
US20250243269A1 (en) Anti-fsh antibodies for neurodegenerative diseases
CN116829582A (zh) 安全施用抗Tau抗体的方法
HK40100358A (zh) 安全施用抗tau抗体的方法
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法
EA047298B1 (ru) Антитела к phf-тау и их применение
HK40105126A (zh) 治疗神经退行性疾病的方法
HK40112634A (zh) 治疗tau病理的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240906

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331